Dr. Sokoloff named chief of urology at University of Arizona
September 11th 2008Mitchell H. Sokoloff, MD, has been appointed chief of the section of urology and professor of surgery at the University of Arizona department of surgery. In this capacity, his objective will be to expand clinical, educational, and research programs in laparoscopy, voiding dysfunction, and urologic cancers, and to build a pediatric urology program in collaboration with university and community physicians.
Patients unaware of link between smoking, bladder cancer
September 11th 2008Although cigarette smoking accounts for up to half of all bladder cancer cases, few people are aware of the connection, including more than three-quarters of patients who have the disease, according to a new study from the University of Michigan Comprehensive Cancer Center, Ann Arbor. This knowledge vacuum suggests that urologists need to communicate the risks of smoking to their patients and encourage them to quit, study authors say.
Obese PCa patients may benefit more from brachytherapy
September 11th 2008Brachytherapy may be a more beneficial treatment than surgery or external beam radiation therapy for overweight or obese prostate cancer patients, according to a study published in the International Journal of Radiation Oncology*Biology*Physics (2008; 71:1302-8).
PSA screening awareness needed among high-risk groups
September 11th 2008One-fifth of men under age 50 reported undergoing a PSA test to detect prostate cancer in the previous year, yet only one in three young African-American men reported ever having had a PSA test in the previous year, according to researchers at the Duke University Prostate Center (Durham, NC). The findings appear in the June 23 online edition of Cancer and will appear in the Sept. 15 print edition.
Subtotal focal therapy for prostate cancer: Not ready for prime time
September 1st 2008Focal cryotherapy, defined as less than complete ablation of the prostate gland with ice, potentially offers targeted local cancer control, preserving sexual potency and urinary continence in patients whose cancer is believed to be unilaterally clinically significant.